139 related articles for article (PubMed ID: 38629593)
1. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study.
Furqan M; Karanth S; Goyal RK; Cai B; Rombi J; Davis KL; Caro N; Saliba T
Future Oncol; 2024 Apr; ():1-11. PubMed ID: 38629593
[No Abstract] [Full Text] [Related]
2. Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and
Asad Zadeh Vosta Kolaei F; Cai B; Kanakamedala H; Kim J; Doban V; Zhang S; Shi M
Front Oncol; 2022; 12():786124. PubMed ID: 35280795
[TBL] [Abstract][Full Text] [Related]
3. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study.
Wolf J; Garon EB; Groen HJM; Tan DSW; Gilloteau I; Le Mouhaer S; Hampe M; Cai C; Chassot-Agostinho A; Reynolds M; Sherif B; Heist RS
Eur J Cancer; 2023 Apr; 183():98-108. PubMed ID: 36822130
[TBL] [Abstract][Full Text] [Related]
5. Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib.
Paik PK; Goyal RK; Cai B; Price MA; Davis KL; Ansquer VD; Caro N; Saliba TR
Future Oncol; 2023 Jan; 19(3):217-228. PubMed ID: 36749292
[No Abstract] [Full Text] [Related]
6. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY
Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494
[TBL] [Abstract][Full Text] [Related]
7. The Current Landscape for
Desai A; Cuellar S
J Adv Pract Oncol; 2022 Jul; 13(5):539-544. PubMed ID: 35910499
[TBL] [Abstract][Full Text] [Related]
8. Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.
Babey H; Jamme P; Curcio H; Assié JB; Veillon R; Doubre H; Pérol M; Guisier F; Huchot E; Decroisette C; Falchero L; Corre R; Cortot A; Chouaïd C; Descourt R
Target Oncol; 2023 Jul; 18(4):585-591. PubMed ID: 37310660
[TBL] [Abstract][Full Text] [Related]
9. Real-world experience with capmatinib in
Illini O; Fabikan H; Swalduz A; Vikström A; Krenbek D; Schumacher M; Dudnik E; Studnicka M; Öhman R; Wurm R; Wannesson L; Peled N; Kian W; Bar J; Daher S; Addeo A; Rotem O; Pall G; Zer A; Saad A; Cufer T; Sorotsky HG; Hashemi SMS; Mohorcic K; Stoff R; Rovitsky Y; Keren-Rosenberg S; Winder T; Weinlinger C; Valipour A; Hochmair MJ
Ther Adv Med Oncol; 2022; 14():17588359221103206. PubMed ID: 35720834
[TBL] [Abstract][Full Text] [Related]
10. Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives.
Fraser M; Seetharamu N; Diamond M; Lee CS
Cancer Manag Res; 2023; 15():1233-1243. PubMed ID: 37941971
[TBL] [Abstract][Full Text] [Related]
11. Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics.
Guo MZ; Marrone KA; Spira A; Waterhouse DM; Scott SC
Onco Targets Ther; 2021; 14():5321-5331. PubMed ID: 34853516
[No Abstract] [Full Text] [Related]
12. Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a
Cai B; Zhou ZY; Xue W; Hazra NC; Singh M; Mishra D; Brixner D; Oderda G; Biskupiak J
J Med Econ; 2021; 24(1):131-139. PubMed ID: 33397178
[TBL] [Abstract][Full Text] [Related]
13. Real-world outcomes among patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first-line setting.
Apple J; Shenolikar R; De Silva K; Sun P; Spira A
Cancer Med; 2023 Jun; 12(12):13415-13425. PubMed ID: 37306623
[TBL] [Abstract][Full Text] [Related]
14. Real-world observational study of current treatment patterns and outcomes in recurrent or locally advanced/metastatic non-small cell lung cancer.
Bazhenova L; Kish J; Cai B; Caro N; Feinberg B
Cancer Treat Res Commun; 2022; 33():100637. PubMed ID: 36162323
[TBL] [Abstract][Full Text] [Related]
15. Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer.
Watari N; Yamaguchi K; Terada H; Hamai K; Masuda K; Nishimura Y; Sakamoto S; Masuda T; Horimasu Y; Miyamoto S; Nakashima T; Iwamoto H; Shoda H; Ishikawa N; Fujitaka K; Miyazaki K; Miyata Y; Hamada H; Awai K; Hattori N
BMC Pulm Med; 2022 Jun; 22(1):260. PubMed ID: 35773658
[TBL] [Abstract][Full Text] [Related]
16. Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14.
Kanemura H; Takeda M; Shimizu S; Nakagawa K
Thorac Cancer; 2021 Feb; 12(4):549-552. PubMed ID: 33347701
[TBL] [Abstract][Full Text] [Related]
17. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
Mazieres J; Vioix H; Pfeiffer BM; Campden RI; Chen Z; Heeg B; Cortot AB
Clin Lung Cancer; 2023 Sep; 24(6):483-497. PubMed ID: 37451931
[TBL] [Abstract][Full Text] [Related]
18. Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.
Julian C; Pal N; Gershon A; Evangelista M; Purkey H; Lambert P; Shi Z; Zhang Q
BMC Cancer; 2023 Apr; 23(1):352. PubMed ID: 37069542
[TBL] [Abstract][Full Text] [Related]
19. Real-world insights into patients with advanced NSCLC and MET alterations.
Bittoni M; Yang JC; Shih JY; Peled N; Smit EF; Camidge DR; Arasada RR; Oksen D; Boutmy E; Stroh C; Johne A; Carbone DP; Paik PK
Lung Cancer; 2021 Sep; 159():96-106. PubMed ID: 34320421
[TBL] [Abstract][Full Text] [Related]
20. Narrative review: mesenchymal-epithelial transition inhibitors-meeting their target.
Safi D; Abu Hejleh T; Furqan M
Transl Lung Cancer Res; 2021 Jan; 10(1):462-474. PubMed ID: 33569327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
